Company intelligence / Profile preview
Everfront Biotech Inc.
Taipei City, Taipei, Taiwanefbiotech.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Phase 2
01
Overview
Cerebraca® Wafer for recurrent high-grade glioma patients has shown a significant median survival period of 26.2 months, surpassing the current therapy of 6-9 months. EF-009 Wafer for pancreatic cancer has demonstrated 1.5 to 2.2-fold extension in mean overall survival compared to control groups in animal studies[6].
- Therapeutic areas
- OncologyPulmonologyNeurology
- Modalities
- Small moleculesbiodegradable implantswafer formulations
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Everfront Biotech Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Everfront Biotech Inc..